AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Baxdrostat for Resistant Hypertension: A Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

By Kumar S, Kumar P, Kumar R et al.

Background: Resistant hypertension (RH), defined as persistently elevated blood pressure despite treatment with three or more antihypertensive agents including a diuretic, affects a substantial proportion of hypertensive patients and is associated with high cardiovascular morbidity and mortality. Excess aldosterone activity is a key pathophysiologic driver. Baxdrostat, a highly selective aldosterone synthase inhibitor, suppresses aldosterone production while sparing cortisol, providing a targeted mechanism for RH management. A comprehensive synthesis of randomized evidence, incorporating recent 2026 trial data, has been lacking. Methods: This systematic review and meta-analysis followed a preregistered PROSPERO protocol (CRD420251038564) and PRISMA 2020 guidelines. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched through December 2025 for randomized controlled trials (RCTs) comparing baxdrostat to placebo in adults with RH. Co-primary efficacy endpoints were changes in systolic (SBP) and diastolic blood pressure (DBP) from baseline. The primary safety outcome was hyperkalemia (serum potassium ≥5.5 mmol/L). Random-effects models were used for pooling. Risk of bias was assessed using Cochrane RoB 2, and evidence certainty was evaluated with GRADE. Results: Five RCTs (BrigHTN, HALO, BaxHTN, Bax24, and Dwyer et al.) totaling 1,996 patients were included. Baxdrostat significantly reduced SBP (mean difference [MD] –6.98 mmHg ; 95% CI –9.78 to –4.18; I ² =93%; P<0.00001) and DBP (MD –3.58 mmHg ; 95% CI –4.40 to –2.75; I ² =51%; P<0.00001). Hyperkalemia risk was increased (risk ratio [RR] 3.77 ; 95% CI 2.29-6.21; I ² =0%; P<0.00001; 103 events with baxdrostat vs. 19 with placebo). Most hyperkalemia cases were mild-to-moderate and manageable. No significant differences occurred in overall or serious adverse events. Conclusions: This meta-analysis of five RCTs (N=1,996) shows baxdrostat significantly reduces SBP and DBP in resistant hypertension via selective aldosterone synthase inhibition, sparing cortisol. Hyperkalemia risk is elevated but manageable, supporting its role as a promising novel therapeutic option.

doi.org/10.1161/circ.154.suppl_1.14652Interventions

AgingResearch.News